Ariel 6 measurements of ultra-heavy cosmic ray fluxes in the region 34 or = Z or = 48

The Ariel VI satellite was launched by NASA on a Scout rocket on 3rd June 1979 from Wallops Island, Virginia, USA, into a near circular 625 km orbit inclined at 55 deg. It carried a spherical cosmic ray detector designed by a group from Bristol University. A spherical aluminum vessel of diameter 75 cm contains a gas scintillation mixture and a thin spherical shell of Pilot 425 plastic, and forms a single optical cavity viewed by 16 photomultipliers. Particle tracks through the detector may be characterized by their impact parameter p and by whether or not they pass through the cup of plastic scintillator placed between the sphere and the spacecraft body (referred to below as the Anti-Coincidence Detector or ACD). Individual particle charges are determined by separately measuring the gas scintillation and the Cerenkov emission from the plastic shell. This is possible because of the quite different distribution in time of these emissions

Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants

BACKGROUND: Before the emergence of the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination reduced transmission of SARS-CoV-2 from vaccinated persons who became infected, potentially by reducing viral loads. Although vaccination still lowers the risk of infection, similar viral loads in vaccinated and unvaccinated persons who are infected with the delta variant call into question the degree to which vaccination prevents transmission. METHODS: We used contact-testing data from England to perform a retrospective observational cohort study involving adult contacts of SARS-CoV-2–infected adult index patients. We used multivariable Poisson regression to investigate associations between transmission and the vaccination status of index patients and contacts and to determine how these associations varied with the B.1.1.7 (alpha) and delta variants and time since the second vaccination. RESULTS: Among 146,243 tested contacts of 108,498 index patients, 54,667 (37%) had positive SARS-CoV-2 polymerase-chain-reaction (PCR) tests. In index patients who became infected with the alpha variant, two vaccinations with either BNT162b2 or ChAdOx1 nCoV-19 (also known as AZD1222), as compared with no vaccination, were independently associated with reduced PCR positivity in contacts (adjusted rate ratio with BNT162b2, 0.32; 95% confidence interval [CI], 0.21 to 0.48; and with ChAdOx1 nCoV-19, 0.48; 95% CI, 0.30 to 0.78). Vaccine-associated reductions in transmission of the delta variant were smaller than those with the alpha variant, and reductions in transmission of the delta variant after two BNT162b2 vaccinations were greater (adjusted rate ratio for the comparison with no vaccination, 0.50; 95% CI, 0.39 to 0.65) than after two ChAdOx1 nCoV-19 vaccinations (adjusted rate ratio, 0.76; 95% CI, 0.70 to 0.82). Variation in cycle-threshold (Ct) values (indicative of viral load) in index patients explained 7 to 23% of vaccine-associated reductions in transmission of the two variants. The reductions in transmission of the delta variant declined over time after the second vaccination, reaching levels that were similar to those in unvaccinated persons by 12 weeks in index patients who had received ChAdOx1 nCoV-19 and attenuating substantially in those who had received BNT162b2. Protection in contacts also declined in the 3-month period after the second vaccination. CONCLUSIONS: Vaccination was associated with a smaller reduction in transmission of the delta variant than of the alpha variant, and the effects of vaccination decreased over time. PCR Ct values at diagnosis of the index patient only partially explained decreased transmission. (Funded by the U.K. Government Department of Health and Social Care and others.

Thermodynamical Bethe Ansatz and Condensed Matter

The basics of the thermodynamic Bethe ansatz equation are given. The simplest case is repulsive delta function bosons, the thermodynamic equation contains only one unknown function. We also treat the XXX model with spin 1/2 and the XXZ model and the XYZ model. This method is very useful for the investigation of the low temperature thermodynamics of solvable systems.Comment: 52 pages, 6 figures, latex, lamuphys.st

Vortex structure in dd-wave superconductors

Vortex structure of pure $d_{x^2-y^2}$-wave superconductors is microscopically analyzed in the framework of the quasi-classical Eilenberger equations. Selfconsistent solution for the $d$-wave pair potential is obtained for the first time in the case of an isolated vortex. The vortex core structure, i.e., the pair potential, the supercurrent and the magnetic field, is found to be fourfold symmetric even in the case that the mixing of $s$-wave component is absent. The detailed temperature dependences of these quantities are calculated. The fourfold symmetry becomes clear when temperature is decreased. The local density of states is calculated for the selfconsistently obtained pair potential. From the results, we discuss the flow trajectory of the quasiparticles around a vortex, which is characteristic in the $d_{x^2-y^2}$-wave superconductors. The experimental relevance of our results to high temperature superconductors is also given.Comment: 22 pages, RevTex, 23 figures available upon reques

Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

Purpose To evaluate risk factors for GI adverse events (AEs) within a phase III trial of bevacizumab in first-line ovarian cancer therapy. Patients and Methods Women with previously untreated advanced disease after surgery were randomly allocated to six cycles of platinum-taxane chemotherapy plus placebo cycles (C)2 to C22 (R1); chemotherapy plus bevacizumab C2 to C6 plus placebo C7 to C22 (R2); or chemotherapy plus bevacizumab C2 to C22 (R3). Patients were evaluated for history or on-study development of potential risk factors for GI AEs defined as grade 2 perforation, fistula, necrosis, or hemorrhage. Results Of 1,873 patients enrolled, 1,759 (94%) were evaluable, and 2.8% (50 of 1,759) experienced a GI AE: 10 of 587 (1.7%, R1), 20 of 587 (3.4%, R2), and 20 of 585 (3.4%, R3). Univariable analyses indicated that previous treatment of inflammatory bowel disease (IBD; P = .005) and small bowel resection (SBR; P = .032) or large bowel resection (LBR; P = .012) at primary surgery were significantly associated with a GI AE. The multivariable estimated relative odds of a GI AE were 13.4 (95% CI, 3.44 to 52.3; P \u3c .001) for IBD; 2.05 (95% CI, 1.09 to 3.88; P = .026) for LBR; 1.95 (95% CI, 0.894 to 4.25; P = .093) for SBR; and 2.15 for bevacizumab exposure (aggregated 95% CI, 1.05 to 4.40; P = .036). Conclusion History of treatment for IBD, and bowel resection at primary surgery, increase the odds of GI AEs in patients receiving first-line platinum-taxane chemotherapy for advanced ovarian cancer. After accounting for these risk factors, concurrent bevacizumab doubles the odds of a GI AE, but is not appreciably increased by continuation beyond chemotherapy

Phenylbutazone: A Clinico-Pharmacological Study in Rheumatoid Arthritis

A clinical trial of phenylbutazone in high dose - 300 mg daily - and low dose - 50 mg daily - is presented. By analysis of the data by different methods, significant differences in clinical efficacy were shown between the two therapeutic regimes. A relationship between the clinical effect and plasma level of phenylbutazone was demonstrated. Some problems in the interpretation of plasma level-clinical effect correlates are discusse

Systematics of Leading Particle Production

Using a QCD inspired model developed by our group for particle production, the Interacting Gluon Model (IGM), we have made a systematic analysis of all available data on leading particle spectra. These data include diffractive collisions and photoproduction at HERA. With a small number of parameters (essentially only the non-perturbative gluon-gluon cross section and the fraction of diffractive events) good agreement with data is found. We show that the difference between pion and proton leading spectra is due to their different gluon distributions. We predict a universality in the diffractive leading particle spectra in the large momentum region, which turns out to be independent of the incident energy and of the projectile type.Comment: 13 pages, Latex, 4 ps figures. To appear in Phys. Rev.

A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates

Tuberculosis is a respiratory disease that is treatable with antibiotics. An increasing prevalence of resistance means that to ensure a good treatment outcome it is desirable to test the susceptibility of each infection to different antibiotics. Conventionally, this is done by culturing a clinical sample and then exposing aliquots to a panel of antibiotics, each being present at a pre-determined concentration, thereby determining if the sample isresistant or susceptible to each sample. The minimum inhibitory concentration (MIC) of a drug is the lowestconcentration that inhibits growth and is a more useful quantity but requires each sample to be tested at a range ofconcentrations for each drug. Using 96-well broth micro dilution plates with each well containing a lyophilised pre-determined amount of an antibiotic is a convenient and cost-effective way to measure the MICs of several drugs at once for a clinical sample. Although accurate, this is still an expensive and slow process that requires highly-skilled and experienced laboratory scientists. Here we show that, through the BashTheBug project hosted on the Zooniverse citizen science platform, a crowd of volunteers can reproducibly and accurately determine the MICs for 13 drugs and that simply taking the median or mode of 11–17 independent classifications is sufficient. There is therefore a potential role for crowds to support (but not supplant) the role of experts in antibiotic susceptibility testing